RXRX (Recursion Pharmaceuticals) Total Equity: $1,024.77 Mil (As of Mar. 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.82
GF Value $4.15
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Total Equity?

Recursion Pharmaceuticals RXRX +3.54% 77 Total Equity is $1,024.77 Mil as of Mar. 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.15 (Fairly Valued). The stock has 4 warning signs investors should review.

Recursion Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $1,024.77 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Recursion Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Total Equity Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 542.94 485.81 463.44 1,034.78 1,130.87

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 933.95 919.15 1,046.95 1,130.87 1,024.77
RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Recursion Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1474.13-343.265
=1,130.87

Recursion Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1339.522-314.753
=1,024.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1,024.77 Mil mean?
Recursion Pharmaceuticals (RXRX) has a Total Equity of $1,024.77 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Total Equity too high?
Recursion Pharmaceuticals' current Total Equity is $1,024.77 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Total Equity compare to ABSI and GLUE?
Recursion Pharmaceuticals' Total Equity of $1,024.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Total Equity is $1,024.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $4.15, compared to a current price of $3.82 — trading 8.1% below its estimated fair value. The current Total Equity is $1,024.77 Mil. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Total Equity is $1,024.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.82 is trading 8.1% below its estimated GF Value™ of $4.15. GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.

Key valuation signals for RXRX:

  • Total Equity: $1,024.77 Mil
  • GF Value™: $4.15 vs. price of $3.82 (8.1% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$4.15
GF Value